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Blocking Programmed Death-1 (PD-1) can reinvigorate exhausted CD8 Tcells (T EX ) and improve control of chronic infections and cancer. However, whether blocking PD-1 can reprogram T EX into durable memory T cells (T MEM ) is unclear. We found that reinvigoration of T EX in mice by PD-L1 blockade caused minimal memory development. After blockade, reinvigorated T EX became reexhausted if antigen concentration remained high and failed to become T MEM upon antigen clearance. T EX acquired an epigenetic profile distinct from that of effector T cells (T EFF ) and T MEM cells that was minimally remodeled after PD-L1 blockade. This finding suggests that T EX are a distinct lineage of CD8 T cells. Nevertheless, PD-1 pathway blockade resulted in transcriptional rewiring and reengagement of effector circuitry in the T EX epigenetic landscape. These data indicate that epigenetic fate inflexibility may limit current immunotherapies. P ersisting antigenic stimulation during chronic infections and cancer can result in T cell exhaustion, a state of impaired effector functions, high expression of inhibitory receptors including Programmed Death-1 (PD-1, or CD279), transcriptional reprogramming, and defective immune memory (1) . Collectively, these properties prevent optimal control of persisting pathogens and tumors. Blocking the PD-1:PD-L1 pathway can reinvigorate exhausted CD8 T cells (T EX ), improving effector functions and enhancing viral and tumor control (1) . Recently developed inhibitors of the PD-1 and cytotoxic T lymphocyteassociated protein 4 (CTLA-4) pathways represent a new paradigm in cancer treatment (2) (3) (4) . Although promising, the majority of patients fail to develop durable responses, and most eventually progress (2) (3) (4) . Thus, it is unclear whether blocking PD-1 can promote long-lasting improvements and immunological memory development in T EX .
To address this question, we analyzed the cellular, transcriptional, and epigenetic changes associated with PD-1 pathway blockade using the mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection (fig. S1, A to C) (5, 6) . After treatment with antibodies against PD-L1 (anti-PD-L1), 1080 genes were up-regulated and 1686 genes were down-regulated [P < 0.05, log 2 fold change (LFC) ≥ 0.2] (Fig. 1A, fig. S1D , and table S1). Previous studies identified transcriptional (7) or cellular (8, 9) changes in metabolic pathways after PD-1 pathway blockade. Indeed, several metabolic genes were altered following PD-L1 blockade (table S1). Gene Set Enrichment Analysis (GSEA), however, identified more prominent changes in cell division pathways (Fig. 1B and table S2) (5, 10) . In addition, many effector-related genes were biased toward the anti-PD-L1 group (Fig. 1 , C and D, and table S3). Other genes of interest included Cxcl9, Il1r2, and Il7r (up-regulated) and Klra9, Tnfrsf9, and Cd200r2 (down-regulated) ( fig. S1D and table S1). Using leading-edge metagene (LEM) analysis (11), we identified two metagenes in anti-PD-L1-treated T EX compared to control T EX ; one corresponding to leukocyte activation and one to cell cycle ( Fig. 1E; fig. S1 , E and F; and table S4). The anti-PD-L1-treated T EX metagenes displayed some overlap with effector T cells (T EFF ), largely driven by cell cycle pathways, but minimal overlap with T MEM (Fig. 1E and table S4 ), suggesting limited acquisition of memory potential upon T EX reinvigoration.
PD-1 pathway blockade can reactivate functions in T EX , but whether reinvigoration is sustained is unclear. There was a robust reinvigoration of T EX , as expected (Fig. 1, F and G, and figs. S1, A and B, and S2) (5), and expansion peaked~3 weeks after initiation of blockade. By 8 to 11 weeks after treatment, however, this reinvigoration was lost, and the quantity, proliferation, effector function, and inhibitory receptor expression of LCMV-specific CD8 T cells in the anti-PD-L1-treated mice were comparable to those in control-treated mice (Fig.  1, F to H, and figs. S2 to S4). Moreover, although anti-PD-L1 treatment reduced viral load immediately after treatment, 4 months later, viral load was similar to that in control-treated mice (Fig. 1I) . Lastly, 18 to 29 weeks after cessation of blockade, the transcriptional profiles of control-and anti-PD-L1-treated groups were similar (Fig. 1J , figs. S5 and S6, and tables S5 and S6). Collectively, these data indicate that when antigen concentration remains high, T EX that were reinvigorated by PD-1 pathway blockade become "reexhausted."
One possible reason the effects of PD-L1 blockade were not sustained is that the infection persisted. We hypothesized that if the infection were cleared, anti-PD-L1 might induce differentiation into T MEM .
To test this idea, we transferred equal numbers of control T EX , anti-PD-L1-treated T EX , or T MEM into antigen-free mice and monitored persistence ( fig. S7A) . Consistent with previous studies (12, 13) , T EX survived poorly in antigen-free recipients compared to functional T MEM (Fig. 2, A and B ). There was a trend toward anti-PD-L1-treated T EX persisting somewhat longer, though survival was poor compared to T MEM (Fig. 2, A and B) . We next investigated potential mechanisms for this trend. After PD-1 pathway blockade, the number of interleukin-7 (IL-7) receptor transcripts (Il7r; CD127) increased significantly ( fig. S1D and table S1). There was also a modest increase in CD127 protein abundance on a subset of T EX after anti-PD-L1 treatment (Fig. 2, C to E) . Upon stimulation with IL-7, anti-PD-L1-treated T EX also showed more phospho-STAT5 (signal transducer and activator of transcription 5) compared to control-treated T EX (Fig. 2F and fig. S7B ). By contrast, expression of the IL-15 receptor subunit CD122 and responsiveness to IL-15 in vitro were not substantially altered (Fig. 2, C and F, and fig.  S7B ). These data suggest that anti-PD-L1 treatment may augment activity of the memory-biased IL-7R pathway.
Treatment with IL-7 starting in the effector phase can prevent development of exhaustion (14, 15) . However, later in chronic infection, T EX respond poorly to IL-7 (12, 13) . Because anti-PD-L1 improved IL-7R signaling, we tested whether combined treatment had additional benefit ( fig. S7C ). Indeed, although other aspects of the response were less affected, treatment with IL-7 and anti-PD-L1, but not IL-7 alone, resulted in more antigenspecific CD8 T cells and improved coproduction of interferon-g (IFN-g) and tumor necrosis factor-a (TNF-a) (Fig. 2, G to H, and fig. S7 , D to H). Thus, it may be possible to exploit pathways up-regulated by PD-L1 blockade, including IL-7R, to improve checkpoint blockade.
We next examined whether PD-1 pathway blockade could restore robust recall potential upon reinfection, a defining property of T MEM . Equal numbers of D b GP33 + CD8 T EX , anti-PD-L1-treated T EX , or T MEM were transferred into antigen-free mice, rested, and then rechallenged with Listeria monocytogenes expressing GP33-41. T MEM robustly expanded and efficiently produced IFN-g (Fig. 3, A to D) . By contrast, both control-and anti-PD-L1-treated T EX mounted poor responses to Listeria-GP33 challenge, and reinvigorated T EX were as defective as control T EX in these key properties (Fig. 3, A to D) . The RNA-seq was performed on two to four independent experiments with 5 to 13 mice per group as indicated in the supplementary methods. Each dot represents an independent replicate. Asterisks indicate statistical significance determined by unpaired t tests between groups (*P < 0.05, **P < 0.01, and ***P < 0.001). ns, not significant.
After antigen withdrawal, T EX and anti-PD-L1-treated T EX failed to down-regulate PD-1 (Fig.  3E) , consistent with Pdcd1 locus DNA methylation and long-term expression of PD-1 (16) (17) (18) . T EX also have lower global diacetylated histone H3 (19) , but how this relates to differentiation is unclear. We hypothesized that the genome-wide epigenetic landscape of T EX may contribute to the lack of durable improvements after PD-1 pathway blockade. Thus, we performed global chromatin landscape mapping using assay for transposaseaccessible chromatin with high-throughput sequencing (ATAC-seq) (20) (fig. S8) (21) . T EFF , T MEM , and T EX showed substantial chromatin remodeling compared to T N (Fig. 3F and fig. S9 , B and C), and genes with transcriptional start sites (TSS) within 20 kb of OCRs tended to be more highly expressed ( fig. S10 ). OCRs at specific genes illustrated distinct patterns for T EFF , T MEM , and T EX. For example, T EX lacked several OCRs present in the Ifng locus in T EFF and T MEM (Fig. 3G , blue boxes). Similarly, for Pdcd1, T EX -specific OCRs were identified in the "B" and "C" regions (Fig. 3G , black box) (9, 22, 23 ) and a previously unidentified OCR~23 kb from the TSS (Fig. 3G, red box) . Global hierarchical clustering and cocluster analysis showed that T EFF and T MEM were more similar to each other than to T EX and that T EX had a distinct global epigenetic landscape (Fig. 3 , H to J, and figs. S11 to S13). These data suggest that T EX may represent a distinct lineage of CD8 T cells.
Two subsets of T EX have been defined based on expression of Eomes, T-bet, and PD-1 (24, 25) , and additional heterogeneity has recently been described (26) (27) (28) i. c . similarity between control and anti-PD-L1-treated T EX (Fig. 3, H to J, and fig. S11 ). OCRs preferentially found in both T EX and anti-PD-L1-treated T EX were located near Pdcd1, Il10, Ctla4, Cxcr5, and elsewhere, suggesting state-specific regulation that was not substantially altered after PD-L1 blockade ( fig. S13 ). Although globally, the epigenetic changes were modest, cocluster analysis identified a small subset of OCRs specifically enriched in T EX (555 peaks) or anti-PD-L1-treated T EX (98 peaks) (Fig. 3, H to I; fig. S13 ; and table S7). Some of these genes showed the same trend epigenetically and transcriptionally (e.g., CD200r; fig. S10E ), and specific biological pathways were enriched in sets of genes near OCRs that were unique to each cell type. (fig. S15 ). T EX displayed~6000 unique OCR changes compared to T EFF and T MEM (Fig. 3, F to I) . Thus, the~6 50 OCR changes induced by PD-L1 blockade were modest by comparison. To determine whether these changes affected specific transcriptional circuits, we identified transcription factor (TF) motifs enriched in peaks gained [e.g., nuclear factor kB (NF-kB), Jun:AP-1 (activator protein 1), and CCCTC-binding factor (CTCF)] or lost [e.g., nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), NFAT:AP1, Nur77, Eomes, and Egr2] (Fig. 4A) . We hypothesized that reinvigoration resulted from rewired transcriptional control within the existing T EX epigenetic landscape. To test this notion, we performed Wellington bootstrap analysis to predict TF binding activity ( Fig. 4B and table S10 ). T EX and anti-PD-L1-treated T EX were more similar to each other than to T N , T EFF , or T MEM . However, TF motifs biased toward T EX or anti-PD-L1-treated T EX were identified ( Fig. 4B and table S10) . TF footprinting was then performed to identify TFs with evidence of likely binding (Fig. 4C and figs. S16 and S17). An integrated network was then constructed for transcriptional circuitry based on predicted TF activity ( Fig. 4D and table S11 ). This network identified augmented activity of NF-kB, interferon regulatory factors (IRFs), and bZip factors (AP-1 family) and decreased activity of NFAT, Egr2, and Nur77 upon PD-L1 blockade. Major features of this transcriptional network were recapitulated with a second network approach in which additional TF families were identified (e.g., Runx, Nr2f6, Prdm1, Rarb, Pparg. Rxra, and homeobox TFs; fig. S18 and table S12). To further investigate how these changes might affect a specific TF, we examined NFAT. NFAT working with AP-1 transactivates many effector-phase SCIENCE sciencemag.org 
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OCRs ATAC enrichment of OCRs genes. By contrast, "partnerless" NFAT that fails to bind AP-1 induces a subset of T EX genes (30) . Here, upon anti-PD-L1 treatment, there was significantly reduced expression of targets of partnerless NFAT in reinvigorated T EX (Fig. 4E) , suggesting a rewiring of this transcriptional circuit after blockade. Together, these data suggested that, although PD-1 pathway blockade did not fully reprogram T EX into T MEM or T EFF , these cells may (re)acquire some features of T EFF biology. One hypothesis is that upon PD-L1 blockade, the rewired transcriptional network allows T EX to preferentially reengage features of their epigenomic program that overlap with T EFF . To test this idea, we separated TF target genes into those containing OCRs that were (i) specific to T EFF , (ii) specific to T EX , or (iii) shared between T EFF and T EX (Fig. 4F) . We then examined the change in genes expressed in each category after PD-L1 blockade. For several TFs, including T-bet and Eomes, there was no redistribution of the pattern of target gene expression (Fig. 4F) . However, for many TFs identified above that have a key role in effector biology, such as NF-kB, IRF1, IRF2, Nur77, and Blimp-1 (encoded by Prdm1), there was an increase in the number of target genes expressed in the T EFF and T EX overlap group compared to the T EX -only group upon PD-L1 blockade (Fig. 4F) . Moreover, genes in the shared T EFF and T EX epigenetic module displayed a substantially greater magnitude of change in expression than genes in the T EX -only group (Fig. 4F) . These data indicate that PD-1 pathway blockade induces rewired transcriptional activity, allowing T EX to more effectively reengage modules of effector genes contained within the epigenetic landscape of T EX . Specific TF circuits that are altered, such as NF-kB, may have implications for cotargeting PD-1 and TNFR family pathways (1, 3, 31 ) and may be relevant for the design of future therapeutics.
Our data suggest that in settings of severe T cell exhaustion, reacquiring durable immune memory may be challenging, especially if tumor or viral antigen persists. However, our data also indicate that PD-1 pathway blockade may reveal opportunities to further augment T cell quality or effector activity (e.g., NF-kB, IL-7R). Additional strategies, such as priming new T cell responses (3), selectively expanding less exhausted subsets (25) , or targeting multiple immunoregulatory or homeostatic pathways (e.g., IL-7, IL-2) simultaneously (1, 3), may also augment acquisition of durable immunity. Finally, these studies provide the impetus for extending epigenetic landscape mapping to human T EX , future evaluation of checkpoint blockade combined with epigenetic modifiers, or epigenomic engineering for T cells. Thus, integrated cellular, transcriptional, and epigenetic profiling of T EX not only reveals mechanistic insights into PD-1 pathway blockade-mediated reinvigoration, NFATc1 -TEX NFκB p65 -αPD- L1   TEFF  TMEM  TN  TEX  αPD-L1  αPD-L1  αPD-L1  TMEM  TN  TEX   TN  αPD-L1  TMEM  TEFF  TEX   TEFF  TN  TEX  TEFF  TMEM  αPD-L1  TEFF  TMEM  TN  TEX   NFkB-p50,p52  bZIP:IRF  IRSE(IRF)  NFkB p65  NFkB p65  AP-1  Atf3  IRF1  IRF2  REST- but also points to key opportunities for improving the long-term durability of these effects.
